# EDGAR Filing Document

**Accession Number:** 0001723980
**File Stem:** 0001213900-25-108213
**Filing Date:** 2025-11
**Character Count:** 8460
**Document Hash:** 86222fb18c361afd9737db7ad187fb91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-108213.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001213900-25-108213

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** China SXT Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001723980
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-282776
- **FILM NUMBER:** 251466277

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 178 TAIDONG ROAD NORTH
- **CITY:** TAIZHOU
- **PROVINCE COUNTRY:** F4
- **BUSINESS PHONE:** 8652386298290

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 178 TAIDONG ROAD NORTH
- **CITY:** TAIZHOU
- **PROVINCE COUNTRY:** F4

**As filed with the Securities and Exchange Commission on November 10, 2025**

**Registration No. 333- 282776**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**Post-Effective Amendment No. 1 to**

**FORM F-3**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**China SXT Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **British Virgin Islands** | **N/A** |
| **(State or other jurisdiction of <br> incorporation or organization)** | **(I.R.S. Employer <br> Identification Number)** |

---

**178 Taidong Rd North, Taizhou**

**Jiangsu, China**

**+86- 523-86298290**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Puglisi & Associates**

**850 Library Avenue**

**Suite 204**

**Newark, Delaware 19711**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

**Lawrence S. Venick, Esq.**

**Loeb & Loeb LLP**

**2206-19 Jardine House**

**1 Connaught Place**

**Central, Hong Kong SAR**

**Telephone: +1 310-728-5129**

**Facsimile: +852-3923-1100**

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of the registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

† The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 **EXPLANATORY NOTE: DEREGISTRATION OF SECURITIES**

This Post-Effective Amendment No. 1 ("Post-Effective Amendment") is filed by China SXT Pharmaceuticals, Inc. (the "Company"), and amends the registration statement initially filed on Form F-3 (File No. [333-282776](http://www.sec.gov/Archives/edgar/data/1723980/000121390024089689/ea0216567-f3_chinasxtpharma.htm)) with the Securities and Exchange Commission (the "Commission") on October 22, 2024 (the "Registration Statement"), registering securities of the Company to be sold using the "shelf registration" process under Rule 415 of the Securities Act of 1933, as amended.

The offering of securities pursuant to the Registration Statement has been abandoned and approximately $29,200,000 of securities were sold under the Registration Statement. Accordingly, pursuant to the undertaking contained in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities that were registered (including Ordinary Shares, debt securities, warrants and Units to purchase such Ordinary Shares, warrants and/or debt securities) that remain unsold, the Company hereby amends the Registration Statement to remove from registration all of the securities covered by the Registration Statement which remain unsold.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Taizhou, China, on November 10, 2025.

---

| | | |
|:---|:---|:---|
| **CHINA SXT PHARMACEUTICALS, INC.** | **CHINA SXT PHARMACEUTICALS, INC.** | **CHINA SXT PHARMACEUTICALS, INC.** |
| By: | /s/ Feng Zhou | /s/ Feng Zhou |
|  | Name: | Feng Zhou |
|  | Title: | Co-Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby constitutes and appoints Feng Zhou as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, in his or her name, place and stead, in any and all capacities (including his capacity as a director and/or officer of the registrant), to sign any and all amendments and post-effective amendments and supplements to this registration statement, and including any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the U.S. Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the U.S. Securities Act of 1933, as amended, this Form F-3 registration statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Position** | **Date** |
| /s/ Feng Zhou | Co-Chief Executive Officer | November 10, 2025 |
| Feng Zhou |  |  |
| /s/ Simon Lim Sze Beng | Co-Chief Executive Officer | November 10, 2025 |
| Simon Lim Sze Beng |  |  |
| /s/ Xiaodong Pan | Chief Financial Officer | November 10, 2025 |
| Xiaodong Pan |  |  |
| /s/ Tong Liu | Director | November 10, 2025 |
| Tong Liu |  |  |
| /s/ Jun Zheng | Director | November 10, 2025 |
| Jun Zheng |  |  |
| /s/ Xiaodong Ji | Director | November 10, 2025 |
| Xiaodong Ji |  |  |
| /s/ Yong Lip Chee | Director | November 10, 2025 |
| Yong Lip Chee |  |  |

---